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Purpose or Objective: To assess and validate the 
incorporation of the multiparametric magnetic resonance 
imaging (mpMRI) tumor stage (mT-stage) to the conventional 
clinical tumor stage (cT-stage), in order to guide the 
radiotherapy (RT) treatment decisions in prostate cancer. In 
addition, to identify the clinical factors associated to the 
technique reliability.  
 
Material and Methods: mpMRI was performed in 274 prostate 
cancer patients in order to refine the treatment decisions 
according to PSA, Gleason Score (GS) and cT-stage. 
Comparisons between the cT and mT-stage were performed, 
as well as the impact on the RT treatment prescription 
(target volume, doses and hormonal therapy [HT]) 
independently if it was finally performed. Changes in HT 
indication for intermediate risk with unfavourable factors 
were also analyzed. Until 2014, the unfavourable factors 
according to the initial criteria were a GS of 7 (4+3), or three 
unfavourable intermediate risk factors (T2b+PSA 10-20 ng/mL 
+ GS 3+4), or T2c by digital rectal exam (DRE)/transrectal 
ultrasound (TRUS); more recently, unfavourable risk factors 
have been established according to Memorial Sloan Kettering 
Cancer Center (MSKCC) criteria: GS 4+3, or at least two 
intermediate-risk factors, or at least one intermediate-risk 
factor and a positive prostate biopsies (ppb) percentage 
greater than 50%. mpMRI validation was performed with 
pathological staging (n=90 patients finally decided to join 
surgery). To analyse the relationship between the reliability 
of mpMRI and the clinical variables, a univariate and 
multivariate logistic regression analysis was performed. 
 
Results: The mpMRI upstaging range was 86-94% for any PSA 
value or GS. Following mpMRI, 32.8% of the patients (90/274) 
were assigned to a different risk group. Compared to cT-
stage, mpMRI identified more intermediate-risk (46.4% vs. 
59.5%) and high-risk (19.0% vs. 28.8%) prostate cancer 
patients. This resulted in a higher indication (p<0.05) of 
seminal vesicle irradiation (63.5% vs. 70.1%), inclusion of any 
extracapsular disease (T3-T4) within the target volume (1.8% 
vs. 18.2%), higher doses (65.3% vs. 88.3%) and more 
indication of HT associated to RT (45.6% vs. 62.4%), Table 1. 
Finally, decisions concerning RT were changed in 43.8% 
(initial criteria) or 52.5% (MSKCC criteria) of the patients, 
depending on the criteria applied to indicate HT in 
intermediate-risk patients. Global reliability of T-staging with 
DRE/TRUS was 8.8% (8/90), while it was 71.1% (64/90) for 
mpMRI. cT-stage was associated to a greater occurrence 
(p<0.05) of indication of inadequate RT treatments. mpMRI 
reliability was independent of PSA or GS or ppb percentage.  
 
 
Conclusion: mpMRI tumor staging significantly improved the 
RT treatment decisions in all prostate cancer risk groups. The 
magnitude of the impact on final RT treatment decisions will 
depend on the institution’s clinical protocol for prostate 
cancer management. 
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Purpose or Objective: SBRT has demonstrated favorable 
outcomes in selected patients with early stage localized 
prostate cancer. Treatment of patients with intermediate 
risk disease remains cautionary due to the heterogeneity 
within this population with respect to risk for occult 
extraprostatic disease. Here we report an analysis of PSA 
outcomes following SBRT for intermediate risk prostate 
cancer and identify disease specific risk factors for 
biochemical failure. 
 
Material and Methods: Patients treated with SBRT at 
Georgetown University Hospital for intermediate risk prostate 
adenocarcinoma, with or without the use of androgen 
deprivation therapy (ADT), were included in this 
retrospective analysis. Treatment was delivered using 
CyberKnife® SBRT with doses of 35 Gy or 36.25 Gy in 5 
fractions. PSA failure was defined as a rise > 2 ng/ml above 
nadir (ASTRO Phoenix definition) and analyzed using the 
Kaplan Meier method. A Cox proportional hazards model was 
generated using disease related covariates including T stage, 
primary gleason pattern, pretreatment PSA, number of 
positive cores, percent positive cores, maximum single core 
involvement in order to identify potential predictors of PSA 
relapse after SBRT. A logrank test was also used to compare 
patients classified as having favorable vs. unfavorable 
intermediate risk disease by previously reported criteria of 
primary gleason pattern 4, ≥ 50% cores involved, or ≥2 
intermediate risk factors. 
 
Results: Three hund;red and fifty three patients at a median 
age of 70 years (range, 46 to 90) received SBRT. ADT was 
initiated prior to SBRT in 16% of patients and the median pre-
ESTRO 35  2016                                                                                                                                                  S345 
________________________________________________________________________________ 
treatment PSA was 7.2 ng/ml (range, 0.8 to 19.9). The 
overall 3-year biochemical relapse free survival (bRFS) was 
93.9%. Cox regression identified primary gleason pattern as 
the only significant predictor of PSA relapse with a HR of 5.84 
(1.92 to 17.8, 95% CI) for primary gleason pattern 4 vs. 3. 
There was no significant difference in bRFS between patients 
classified as having favorable vs. unfavorable intermediate 
risk disease, HR 0.39 (0.11 to 1.41, 95% CI). There were no 
significant benefits observed with respect to ADT in any 
subgroup. 
 
Conclusion: Early PSA responses after SBRT for intermediate 
risk prostate adenocarcinoma compare favorably to those 
reported using other radiation therapy modalities. Primary 
gleason pattern 4 is predictive of less favorable bRFS, 
however early rates of PSA control are excellent compared to 
historical controls. The role of ADT in these patients is still 
unclear. The current evidence supports SBRT as a standard 
therapeutic option in intermediate risk disease. 
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Purpose or Objective: The aim of the study was to compare 
health-related quality of life (QoL) after external beam 
radiotherapy (RT) for prostate cancer with and without a 
hydrogel spacer. 
 
Material and Methods: A group of 202 patients with the 
indication for treatment of the prostate +/- base of seminal 
vesicles without pelvic lymph nodes was treated in a single 
institution in the years 2010-2013. Depending on the 
patient’s and responsible radiation oncologist’s preference, 
108 patients were selected for a hydrogel injection before 
the beginning of RT. The injection of 10 ml hydrogel was 
performed under transrectal ultrasound (TRUS) guidance 
after dissecting the space between prostate and rectum with 
a saline/lidocaine solution under local anaesthesia. 
Treatment was performed with a five-field IMRT or VMAT 
technique with daily ultrasound based image guidance. Only 
for patients with a spacer the prescription dose was 
increased from 76Gy to 78Gy, subsequently 80Gy. Patients 
were surveyed prospectively before RT (time A), at the last 
day of RT (time B), a median time of two months (time C) 
and seventeen months after RT (time D) using a validated 
questionnaire (Expanded Prostate Cancer Index Composite; 
comprising 50 items concerning urinary, bowel, sexual and 
hormonal domains). The multi-item scale scores were 
transformed lineary to a 0-100 scale, with higher scores 
representing better QoL. Baseline QoL assessment was 
available from 101 / 66 patients with / without a spacer. 
Responses to both the baseline and last (time D) 
questionnaire were available in 94 / 57 cases with / without 
a spacer. 
 
Results: Apart from higher prescription doses in the spacer 
group, baseline patient characteristics were well balanced 
between patients with vs. without a spacer (Table). In 
particular, baseline QoL was comparable. Acute toxicity 
(corresponding to QoL changes at times B and C relative to 
baseline levels) did not differ significantly, with only a 
tendency for better scores in the spacer group. However, 
mean bowel bother scores >1 year after RT in comparison to 
baseline did not change for patients with a spacer (mean 
change of 0 points) in contrast to patients without a spacer 
(mean decrease of 7 points). Long-term mean urinary bother 
scores did not decrease in both groups. At time D, 
statistically significant differences were found in the function 
items “bloody stools”, “painful bowel movements” and 
“frequency of bowel movements”. Focusing on patients with 
no problem with bowel symptoms initially, 0% vs. 12% with 
vs. without a spacer reported a moderate/big problem with 
bowel symptoms >1 year after RT (p<0.01). 
 
 
Conclusion: Though acute rectal symptoms are still reported, 
spacer injection is associated with a significant long-term 
benefit for patients after prostate cancer RT. 
 
PO-0739  
IMRT versus 3D conformal radiotherapy when used in 
combination with I-125 prostate brachytherapy 
A. Yorozu
1Tokyo Medical Centre- NHO, Department of Radiation 
Oncology, Tokyo, Japan 
1, T. Tanaka1, R. Kota1, Y. Takagawa1, Y. Shiraishi1, 
K. Toya1, S. Saito2 
2Tokyo Medical Centre- NHO, Department of Urology, Tokyo, 
Japan 
 
Purpose or Objective: To compare biochemical outcomes 
and toxicity of intensity modulated radiotherapy (IMRT) and 
three-dimensional conformal radiotherapy (3D-CRT) when 
used in combination with I-125 brachytherapy (BT) for the 
treatment of unfavorable-risk prostate cancer. 
 
Material and Methods: A retrospective review was performed 
on 839 patients with localized prostate cancer who received 
external-beam radiotherapy (EBRT) following BT between 
2003 and 2012. Patients were categorized into National 
Comprehensive Cancer Network risk groups: 616 were 
unfavorable intermediate-risk (Gleason score 4+3, or Gleason 
score 3+4 with positive biopsy core rate >1/3), and 223 were 
high-risk. Treatment begins with BT, followed 6 weeks later 
by 45 Gy/25 fractions of EBRT. EBRT was delivered via 3D-
CRT in 616 men at first and via IMRT technique for 223 men 
after 2010. The prescription dose for I-125 was 100 Gy, up to 
110 Gy after 2009. All patients underwent a CT scan for 
postplan dosimetry at day 30. The rectal volumes receiving 
doses higher than 30 Gy, 35 Gy, and 40Gy should be kept 
under 35%, 25%, and 15%, respectively. Neoadjuvant 
androgen deprivation therapy was given to 45% of patients. 
Biochemical failure was defined with the Phoenix criteria, 
and toxicity was graded according to the National Cancer 
Institute’s Common Terminology Criteria for Adverse Events, 
prospectively collected. The median (range) follow-up was 7 
(2-12) years for the entire cohort; 8.3 years for 3D-CRT, and 
4.3 years for IMRT. The biological effective dose (BED) was 
calculated using an α/β of 2 Gy and the D90 values of the 
prostate on a day-30 CT scan. Comparisons were made by 
chi-square test and log-rank test. 
 
Results: The total BED value of the prostate was higher in the 
IMRT group than in the 3D-CRT group (219 Gy2 vs. 209 Gy2, p 
<0.001). The 5-year actuarial freedom from biochemical 
failure for the IMRT group vs. the 3D-CRT group were 92.7% 
vs. 92.6% (p=0.825) for all; 95.4% vs. 95.1% for intermediate-
risk, and 88.0% vs. 84.8% for high-risk group (p=0.788), 
respectively. Acute gastrointestinal (GI) grade 2+ toxicities 
occurred in 0.5% of the IMRT group and 2.7% of the 3D-CRT 
